A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ultimately require transplantation, according to new research from Rutgers Health.

Editing genomico eseguito su un neonato con una grave malattia rara

ANSA

Italy

Genome editing performed on a newborn with a serious rare disease

Genome editing was performed on a newborn with a rare and potentially fatal disease, ornithine transcarbamylase (OTC) deficiency at neonatal onset, which compromises the body's ability to dispose of ammonia, toxic to organs: the company... (BEND)

Eseguito l'editing genomico su un neonato con malattia rara e potenzialmente fatale, il deficit di ornitina transcarbamilasi (OTC) all'esordio neonatale, che compromette la capacità dell'organismo di smaltire l'ammoniaca, tossica per gli organi: l'azienda ... (ANSA)

Media Bias/Fact Check

Medical Xpress

Decades-old allergy drug shows potential for treating liver complications in rare genetic disease

Ad Fontes Media

News Medical

Ian Birkby

United States

Antihistamine shows promise for treating rare genetic liver disease

Recent research has unveiled a striking potential application for chlorcyclizine, a common antihistamine historically utilized in allergy treatments. According to the latest findings published by researchers at Rutgers Health, this medication may hold promise for treating erythropoietic protoporphyria (EPP), a rare genetic disorder that can lead to severe liver damage and may necessitate a liver transplant. The implications of this discovery cou…

BIOENGINEER.ORG

Promising Findings: Common Antihistamine May Alleviate Liver Complications

There are therapeutic treatments available for cholestatic liver disease (CHD), but they are limited, as the biochemical response to first-line treatment with ursodeoxycholic acid is associated with important complications in approximately 40% of patients with primary biliary cholangitis (CBP), a rare form of immune-mediated HHD. Now, a new study recently published in the renowned scientific journal Hepatology shows a crucial role of Stard1 prot…

Hay tratamientos terapéuticos disponibles para la enfermedades hepáticas colestáticas (EHC), pero son limitados, ya que la respuesta bioquímica al tratamiento de primera línea con ácido ursodesoxicólico se asocia con complicaciones importantes en aproximadamente el 40 % de los pacientes con colangitis biliar primaria (CBP), una forma rara de EHC mediada por el sistema inmunitario. Ahora, un nuevo estudio recientemente publicado en la reconocida …

Antihistamine shows promise for treating rare genetic liver disease

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics